Dumontet C - Search Results

1

A revised nomenclature for the human and rodent alpha-tubulin gene family.

Khodiyar VK, Maltais LJ, Ruef BJ, Sneddon KM, Smith JR, Shimoyama M, Cabral F, Dumontet C, Dutcher SK, Harvey RJ, Lafanechère L, Murray JM, Nogales E, Piquemal D, Stanchi F, Povey S, Lovering RC. Khodiyar VK, et al. Among authors: dumontet c. Genomics. 2007 Aug;90(2):285-9. doi: 10.1016/j.ygeno.2007.04.008. Epub 2007 Jun 1. Genomics. 2007. PMID: 17543498 Free article.

2

Protein abundance of class III beta-tubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site.

Sève P, Reiman T, Isaac S, Trillet-Lenoir V, Lafanéchère L, Sawyer M, Dumontet C. Sève P, et al. Among authors: dumontet c. Anticancer Res. 2008 Mar-Apr;28(2B):1161-7. Anticancer Res. 2008. PMID: 18505052 Free article.

3

Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.

Sève P, Isaac S, Trédan O, Souquet PJ, Pachéco Y, Pérol M, Lafanéchère L, Penet A, Peiller EL, Dumontet C. Sève P, et al. Among authors: dumontet c. Clin Cancer Res. 2005 Aug 1;11(15):5481-6. doi: 10.1158/1078-0432.CCR-05-0285. Clin Cancer Res. 2005. PMID: 16061864

4

Tubulin detyrosination is a frequent occurrence in breast cancers of poor prognosis.

Mialhe A, Lafanechère L, Treilleux I, Peloux N, Dumontet C, Brémond A, Panh MH, Payan R, Wehland J, Margolis RL, Job D. Mialhe A, et al. Among authors: dumontet c. Cancer Res. 2001 Jul 1;61(13):5024-7. Cancer Res. 2001. PMID: 11431336

5

BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy.

Dumontet C, Krajewska M, Treilleux I, Mackey JR, Martin M, Rupin M, Lafanechère L, Reed JC. Dumontet C, et al. Clin Cancer Res. 2010 Aug 1;16(15):3988-97. doi: 10.1158/1078-0432.CCR-10-0079. Epub 2010 Jun 24. Clin Cancer Res. 2010. PMID: 20576719

6

Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth.

Prudent R, Vassal-Stermann E, Nguyen CH, Pillet C, Martinez A, Prunier C, Barette C, Soleilhac E, Filhol O, Beghin A, Valdameri G, Honoré S, Aci-Sèche S, Grierson D, Antonipillai J, Li R, Di Pietro A, Dumontet C, Braguer D, Florent JC, Knapp S, Bernard O, Lafanechère L. Prudent R, et al. Among authors: dumontet c. Cancer Res. 2012 Sep 1;72(17):4429-39. doi: 10.1158/0008-5472.CAN-11-3342. Epub 2012 Jul 3. Cancer Res. 2012. PMID: 22761334 Free article.

7

Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?

Sève P, Dumontet C. Sève P, et al. Among authors: dumontet c. Lancet Oncol. 2008 Feb;9(2):168-75. doi: 10.1016/S1470-2045(08)70029-9. Lancet Oncol. 2008. PMID: 18237851 Review.

8

[Class III beta tubulin expression in nonsmall cell lung cancer].

Sève P, Dumontet C. Sève P, et al. Among authors: dumontet c. Rev Mal Respir. 2010 Apr;27(4):383-6. doi: 10.1016/j.rmr.2010.03.006. Epub 2010 Mar 25. Rev Mal Respir. 2010. PMID: 20403547 Review. French.

9

The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site.

Sève P, Billotey C, Broussolle C, Dumontet C, Mackey JR. Sève P, et al. Among authors: dumontet c. Cancer. 2007 Jan 15;109(2):292-9. doi: 10.1002/cncr.22410. Cancer. 2007. PMID: 17167760 Free article. Review.

10

[Can tumor hypoxia be turned into a chemotherapeutic advantage?].

Trédan O, Grantab R, Dumontet C. Trédan O, et al. Among authors: dumontet c. Bull Cancer. 2008 May;95(5):528-34. doi: 10.1684/bdc.2008.0637. Bull Cancer. 2008. PMID: 18541517 Review. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

403 results

Search Page

Filters